Search

Background. Proteinuria during pregnancy has been associated with increased pregnancy complications. Furthermore, even low-grade proteinuria has been associated with increased mortality in the general population and in non-pregnant HIV-infected women.Methods. Urine dipstick protein was measured prospectively on HIV-infected and trace protein or more and quantified by urine protein:creatinine measurement (P:C). Logistic regression modeling was used to identify factors associated with proteinuria.Results. About 199 human immunodeficiency virus (HIV)-infected and 190 HIV-uninfected normotensive pregnant women were evaluated. The median age was 27 years in both groups and 37% presented in the third trimester. Among HIV-infected women, median CD4 cell count was 417 cells/mm3; 27% were on combination antiretroviral therapy (cART). Proteinuria was present in 39.2% of HIV-infected and 20.9% of uninfected women (P < 0.001). HIV infection was independently associated with proteinuria [adjusted odds ratio (OR) = 2.45; confidence interval (CI) = 1.56–3.85]. Among HIV-infected pregnant women, cART was protective (adjusted OR = 0.39; CI = 0.19–0.82). Results were qualitatively similar when urine P:C was evaluated as a continuous outcome variable.Conclusions. The prevalence of low-grade proteinuria in both HIV-infected and -uninfected Cameroonian pregnant women is high. HIV-infected pregnant women are at increased risk for proteinuria, and cART appears to exert a protective effect. Further studies are needed to elucidate the causes of increased proteinuria in African pregnant women, both HIV-infected and -uninfected. [ABSTRACT FROM PUBLISHER]

Context: Intrauterine HIV/antiretroviral (ARV) and postnatal ARVs are known to perturb energy metabolism and could have permanent effects on future metabolic health. Such maladaptive effects could be mediated by changes in mitochondrial function and intermediary metabolism due to fetal and early-life ARV exposure in HIV/ARV-exposed uninfected (HEU) infants., Objective: The objective of the study was to understand the relationship(s) between mitochondrial fuel use (assessed via acylcarnitines and branched chain amino acids) and preprandial insulin in infants exposed to in utero HIV/ARV plus postnatal zidovudine or nevirapine compared with HIV/ARV-unexposed uninfected (HUU) infants., Design: This was a prospective cohort study with the following three groups: 1) intrauterine HIV/ARV/postnatal zidovudine-exposed (HEU-A), 2) intrauterine HIV/ARV/postnatal nevirapine-exposed (HEU-N), and 3) HUU infants. Principal component analysis and linear regression modeling were performed to assess the association between in utero HIV/ARV exposure and infant insulin., Setting: The study was conducted at Cameroonian urban antenatal centers., Participants: HIV-infected and -uninfected pregnant woman/infant dyads participated in the study., Main Outcome: Preprandial insulin was the main outcome measured., Results: Of 366 infants, 38 were HEU-A, 118 HEU-N. Forty intermediary metabolites were consolidated into seven principal components. In a multivariate analysis, both HEU-A (β = -.116, P= .012) and HEU-N (β = -.070, P= .022) demonstrated lower insulin compared with HUU infants. However, at high levels of plasma metabolites, HEU-A (β = .027, P= .050) exhibited higher insulin levels than HEU-N or HUU infants. A unique array of short-chain acylcarnitines (β = .044, P= .001) and branched-chain amino acids (β = .033, P= .012) was associated with insulin., Conclusion: HEU-A and HEU-N infants have lower preprandial insulin levels at 6 weeks of age and appear to use metabolic fuel substrates differently than HUU infants. Future studies are warranted to determine whether observed differences have lasting metabolic implications, such as later insulin resistance.